Quick Answer
Allogene Therapeutics, Inc. reported R&D Expense of $150.15 million for fiscal year 2025.
Allogene Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $150.15M | -21.9% |
| 2024 | $192.30M | -20.8% |
| 2023 | $242.91M | -5.3% |
| 2022 | $256.39M | +16.4% |
| 2021 | $220.18M | +14.1% |
| 2020 | $192.99M | +33.5% |
| 2019 | $144.53M | -4.8% |
| 2018 | $151.86M | — |
| 2017 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.16M | -30.3% | -22.4% |
| June 30, 2025 | $40.16M | -20.3% | -20.0% |
| March 31, 2025 | $50.20M | -3.9% | +12.3% |
| September 30, 2024 | $44.71M | -2.7% | -11.2% |
| June 30, 2024 | $50.35M | -18.8% | -3.6% |
| March 31, 2024 | $52.26M | -34.9% | +13.7% |
| September 30, 2023 | $45.98M | -27.8% | -25.9% |
| June 30, 2023 | $62.04M | +8.5% | -22.7% |
- Allogene Therapeutics, Inc. showed a decrease of -21.9% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: